CXCR7: a novel tumor endothelial marker in renal cell carcinoma (Q39360771)

11 September 2017

title

CXCR7: a novel tumor endothelial marker in renal cell carcinoma (English)

1 reference

11 September 2017

0 references

Nako Maishi

1 reference

11 September 2017

Noritaka Ohga

1 reference

11 September 2017

Yasuhiro Hida

1 reference

11 September 2017

Kosuke Akiyama

1 reference

11 September 2017

Kazuko Kitayama

1 reference

11 September 2017

Takahiro Osawa

1 reference

11 September 2017

Yuichiro Onodera

1 reference

11 September 2017

Nobuo Shinohara

1 reference

11 September 2017

Katsuya Nonomura

1 reference

11 September 2017

Masanobu Shindoh

1 reference

11 September 2017

Kyoko Hida

1 reference

11 September 2017

publication date

21 February 2012

1 reference

11 September 2017

published in

Pathology International

1 reference

11 September 2017

1 reference

11 September 2017

1 reference

11 September 2017

page(s)

309-317

1 reference

Angiogenesis in life, disease and medicine

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

VEGF as a key mediator of angiogenesis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

Antiangiogenesis drug promising for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

Isolated tumor endothelial cells maintain specific character during long-term culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

Inhibitory effects of epigallocatechin-3 gallate, a polyphenol in green tea, on tumor-associated endothelial cells and endothelial progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

Antiangiogenic treatments and mechanisms of action in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

Essential but differential role for CXCR4 and CXCR7 in the therapeutic homing of human renal progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

HOXB13 promotes ovarian cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

Signalling pathway mediated by CXCR7, an alternative chemokine receptor for stromal-cell derived factor-1α, in AtT20 mouse adrenocorticotrophic hormone-secreting pituitary adenoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

Vascular gene expression in nonneoplastic and malignant brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

The role of stromal-derived factor-1--CXCR7 axis in development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

Expression of CXCR7 chemokine receptor in human meningioma cells and in intratumoral microvasculature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

Tumor-associated endothelial cells with cytogenetic abnormalities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

Cyclooxygenase‐2 inhibition causes antiangiogenic effects on tumor endothelial and vascular progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

Effect of the chemokine receptor CXCR7 on proliferation of carcinoma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

Angiogenesis in cancer, vascular, rheumatoid and other disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

The SDF-1-CXCR4 axis stimulates VEGF secretion and activates integrins but does not affect proliferation and survival in lymphohematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2012.02792.X

10.1111/J.1440-1827.2012.02792.X

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference